内容紹介
Metastatic Breast Cancer with Microangiopathic Hemolytic Anemia Successfully Treated by Using Eribulin
Summary
A 48-year-old woman was diagnosed with metastatic breast carcinoma and multiple bone metastases as well as a brain metastasis in 2004. Multiple bone metastases and brain metastases were also diagnosed in 2005, 2006, and 2010, but she remained stable with the use of chemotherapy and hormonal therapy for about 8 years. In 2013, severe anemia occurred, and the patient was diagnosed with microangiopathic hemolytic anemia(MHA). She was treated with eribulin(1.4 mg/m2), and recovered successfully after treatment. Approximately 8 months have elapsed after initiating the therapy, and there has been no recurrence. MHA associated with breast cancer is very rare, and is regarded as a disease with a poor prognosis. However, eribulin could be a valid treatment for prolonging the survival of patients with MHA associated with breast cancer.
要旨
症例は48歳,女性。2004年に乳癌stageⅣ(多発骨転移,脳転移)と診断。骨転移,脳転移の増悪を繰り返すが,化学療法,ホルモン療法にて病態は安定していた。2013年に高度貧血を呈し,精査の結果,細小血管障害性溶血性貧血と診断された。eribulin(1.4 mg/m2)にて治療を開始したところ貧血は改善し,治療開始後8か月経過した時点で再燃を認めていない。細小血管障害性溶血性貧血はまれな病態であり予後不良とされているが,eribulinが有効な治療法になる可能性がある。
目次
Summary
A 48-year-old woman was diagnosed with metastatic breast carcinoma and multiple bone metastases as well as a brain metastasis in 2004. Multiple bone metastases and brain metastases were also diagnosed in 2005, 2006, and 2010, but she remained stable with the use of chemotherapy and hormonal therapy for about 8 years. In 2013, severe anemia occurred, and the patient was diagnosed with microangiopathic hemolytic anemia(MHA). She was treated with eribulin(1.4 mg/m2), and recovered successfully after treatment. Approximately 8 months have elapsed after initiating the therapy, and there has been no recurrence. MHA associated with breast cancer is very rare, and is regarded as a disease with a poor prognosis. However, eribulin could be a valid treatment for prolonging the survival of patients with MHA associated with breast cancer.
要旨
症例は48歳,女性。2004年に乳癌stageⅣ(多発骨転移,脳転移)と診断。骨転移,脳転移の増悪を繰り返すが,化学療法,ホルモン療法にて病態は安定していた。2013年に高度貧血を呈し,精査の結果,細小血管障害性溶血性貧血と診断された。eribulin(1.4 mg/m2)にて治療を開始したところ貧血は改善し,治療開始後8か月経過した時点で再燃を認めていない。細小血管障害性溶血性貧血はまれな病態であり予後不良とされているが,eribulinが有効な治療法になる可能性がある。